# OnCo record veno-occlusive-disease-on-inotuzumab-and-gemtuzumab-ozogamicin (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/veno-occlusive-disease-on-inotuzumab-and-gemtuzumab-ozogamicin/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "veno-occlusive-disease-on-inotuzumab-and-gemtuzumab-ozogamicin" ;
  schema:name "Liver toxicity and veno-occlusive disease on inotuzumab ozogamicin and gemtuzumab ozogamicin: risk reduction, monitoring, hold and stop rules"@en ;
  schema:alternateName "VOD on inotuzumab"@en, "SOS on inotuzumab ozogamicin"@en, "veno-occlusive disease on Besponsa"@en, "veno-occlusive disease on Mylotarg"@en, "sinusoidal obstruction syndrome on gemtuzumab ozogamicin"@en, "calicheamicin liver toxicity"@en, "raised liver enzymes on inotuzumab ozogamicin"@en, "inotuzumab cycles before transplant"@en, "hepatotoxicity on gemtuzumab ozogamicin"@en ;
  schema:description "Inotuzumab ozogamicin and gemtuzumab ozogamicin can harm the liver and can block its small blood vessels (veno-occlusive disease), more often when a transplant follows. Liver blood tests are taken around each dose, a dose is delayed if they rise, and the drug is stopped if the blockage occurs. Fast weight gain, a swollen or painful tummy or yellow skin need a call to your team at once."@en ;
  schema:url <https://onco.cc/protocols/veno-occlusive-disease-on-inotuzumab-and-gemtuzumab-ozogamicin/> ;
  schema:dateModified "2026-11-18"^^xsd:date ;
  onco:related <https://onco.cc/protocols/hepatic-veno-occlusive-disease-after-transplant/>, <https://onco.cc/protocols/raised-liver-enzymes-on-targeted-anticancer-drugs/>, <https://onco.cc/pairings/inotuzumab-then-transplant-caution/>, <https://onco.cc/protocols/hct-conditioning-and-engraftment-care/>, <https://onco.cc/protocols/hepatic-dose-adjustment-of-anticancer-drugs/>, <https://onco.cc/drugs/defibrotide/>, <https://onco.cc/technologies/allogeneic-hsct/> ;
  onco:drugs <https://onco.cc/drugs/inotuzumab-ozogamicin/>, <https://onco.cc/drugs/gemtuzumab-ozogamicin/> ;
  onco:terms <https://onco.cc/terms/hepatotoxicity/>, <https://onco.cc/terms/conditioning-regimen/>, <https://onco.cc/terms/dose-modification/> .
